Medical News

RSS

CXCR4 protein restores brain damage in multiple sclerosis patients

A protein that helps build the brain in infants and children may aid efforts to restore damage from multiple sclerosis (MS) and other neurodegenerative diseases, researchers at Washington University School of Medicine in St. Louis have found.

9 Jun 2010

RCSI scientists make breakthrough in understanding human adaptation to high altitude environments

A group of top international scientists including geneticists from the Royal College of Surgeons in Ireland has made a breakthrough in understanding human adaptation to high altitude environments.

9 Jun 2010

DuPont reaches regulatory milestone with confirmation of Plenish high oleic soybean trait

DuPont announced it has reached a regulatory milestone and the final step of the U.S. regulatory process with confirmation from the United States Department of Agriculture that its Plenish high oleic soybean trait has been approved for cultivation in the United States.

9 Jun 2010

Personality traits influence reproductive success

The reproductive success of both men and women is influenced by our personality traits, according to new research from the University of Sheffield.

9 Jun 2010

New report compares U.S. and European funding for research related to synthetic biology

A new analysis by the Synthetic Biology Project at the Woodrow Wilson Center found that the U.S. government has spent around $430 million on research related to synthetic biology since 2005, with the Department of Energy funding a majority of the research. By comparison, the analysis indicated that the European Union and three individual European countries – the Netherlands, United Kingdom, and Germany – had spent approximately $160 million during that same period.

9 Jun 2010

Simcyp releases Population-based ADME Simulator Version 10.0

Simcyp Limited today announces that it has released the latest version of its flagship simulator, further cementing its position as the industry leader in modelling and simulation of drug-drug interactions (DDIs) in virtual populations.

9 Jun 2010

Forterus signs agreements with J.P. Morgan Chase and other independent investors

Forterus, Inc. today announced that it has signed agreements with J.P. Morgan Chase & Co. and other independent investors to provide financing to qualified consumers seeking behavioral healthcare services.

9 Jun 2010

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.

9 Jun 2010

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Northwest Biotherapeutics, Inc., developer of the DCVax personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr. Navid Malik of the London-based Matrix Group.

9 Jun 2010

Connections project to debate effectiveness of drug and alcohol interventions within criminal justice system

The second annual European gathering of the Connections project, a University of Kent-managed project co-funded by the European Commission Public Health Programme, will debate the ethics, effectiveness and economics of drug and alcohol interventions within the criminal justice system.

9 Jun 2010

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of its proposed Phase II clinical study of CH-4051 in rheumatoid arthritis and indicated that the agency is requesting additional detail from the preclinical studies previously submitted as part of the company's investigational new drug application.

9 Jun 2010

Faith-based HIV-prevention program for African-American women and girls

Developing and evaluating a faith-based, HIV-prevention program for African-American mothers and their daughters is the focus of Dr. Chisina Kapungu's $795,000 career development grant from the National Institute of Mental Health.

9 Jun 2010

Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

Human Genome Sciences, Inc. today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma.

9 Jun 2010

LUMEDX certified as official ACC-NCDR ICD Registry 2.0 software vendor

The American College of Cardiology has certified LUMEDX Corporation--the industry leader in integrated cardiovascular information systems and the number one provider of ACC software--as an official ACC-NCDR ICD Registry 2.0 software vendor. LUMEDX's Export to ICD Registry solution is the latest in a suite of software applications developed to address the growing need for impeccable, accessible cardiovascular data, streamlined clinical workflows and superior data management.

9 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

Additional markers of risk for diabetic microvascular complications beyond Hemoglobin A1c needed

The "gold standard" diabetes test, Hemoglobin A1c (A1C), explains much less about the risk of cardiovascular complications in patients with diabetes than originally thought, according to an article in the June 9 issue of the Journal of the American Medical Association (JAMA). The article entitled, "Beyond HbA1c: Need for Additional Markers of Risk for Diabetic Microvascular Complications," was co-authored by Irl Hirsch, M.D., of the University of Washington Medical School (Seattle, WA) and Michael Brownlee, M.D., of the Albert Einstein College of Medicine.

9 Jun 2010

Delaware's first-in-the-nation guidelines for nutrition and physical activity in child care accepted: Study

A study conducted by the nonprofit health research organization Altarum Institute suggests that Delaware's first-in-the-nation guidelines for nutrition and physical activity in child care are broadly accepted by both child care providers and parents, and that challenges to implementing the policies can be overcome with support.

9 Jun 2010

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).

9 Jun 2010

Stress-reducing psychological intervention helps increase quality of life among women with breast cancer

Stress-reducing psychological intervention helps to increase survival and quality of life among women with recurrent breast cancer over the long-term, according to results of a Phase III study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

9 Jun 2010

Lapses in infection control common in ambulatory surgical centers

An assessment of nearly 70 ambulatory surgical centers in three states found that lapses in infection control were common, including for practices such as hand hygiene, injection and medication safety and equipment reprocessing, according to a study in the June 9 issue of JAMA.

9 Jun 2010

Medical News

CXCR4 protein restores brain damage in multiple sclerosis patients

RCSI scientists make breakthrough in understanding human adaptation to high altitude environments

DuPont reaches regulatory milestone with confirmation of Plenish high oleic soybean trait

Personality traits influence reproductive success

New report compares U.S. and European funding for research related to synthetic biology

Simcyp releases Population-based ADME Simulator Version 10.0

Forterus signs agreements with J.P. Morgan Chase and other independent investors

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Connections project to debate effectiveness of drug and alcohol interventions within criminal justice system

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Faith-based HIV-prevention program for African-American women and girls

Human Genome Sciences reports results of mapatumumab Phase 2 trial for multiple myeloma

LUMEDX certified as official ACC-NCDR ICD Registry 2.0 software vendor

Some commonly used drugs cause bone loss: New research

Additional markers of risk for diabetic microvascular complications beyond Hemoglobin A1c needed

Delaware's first-in-the-nation guidelines for nutrition and physical activity in child care accepted: Study

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Stress-reducing psychological intervention helps increase quality of life among women with breast cancer

Lapses in infection control common in ambulatory surgical centers

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News